AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2019 – Poster

Oct 29, 2019

Antitumor activity of STRO-002, a novel anti-folate receptor -⍺ (FolR⍺) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary Phase I dose escalation safety outcomes in patients with ovarian carcinoma (OC)

Please Click the Link, AACR NCI EORTC 2019 Poster to Enlarge

Sutro Biopharma, Inc.
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.